Scholar Rock Holding Corp
SRRKNasdaq
$52.86
↑ +2.2%Jul 17 close · end-of-day
Price
1Y↑ +28.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.7B
Enterprise Value
$6.4B
P/E
—
P/S
—
P/B
24.4
EV/EBITDA
—
PEG
—
FCF Yield
-4.5%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$408.8M
Free Cash Flow (TTM)
-$303.9M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-148.1%
ROIC
—
Debt / Equity
0.7
Net Cash
$283.3M
Return 1Y
+23.3%
Company profile
Scholar Rock Holding Corporation focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin, and SRK-181, which is in Phase 1 clinical trials. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients.
- CEO
- Jay T. Backstrom
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 140
- Headquarters
- Massachusetts
- Website
- scholarrock.com
Management & directors
- Hallal DavidChief Executive Officer
- Sinha VikasChief Financial Officer
- Vaishnaw AkshayPresident of R&D
- Woods KeithChief Operating Officer
- Qatanani MoCHIEF SCIENTIFIC OFFICER
- Ho JunlinGENERAL COUNSEL
- Marantz Jing L.CHIEF MEDICAL OFFICER
- Parlavecchio CarynChief Human Resources Officer
Roles derived from SEC Form 4 filings.
Earnings
SRRK Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.83↑ +23.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $15.4M | $18.8M | $33.2M | — | — | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$86.9M | -$129.9M | -$134.4M | -$171.3M | -$252.1M | -$384.6M |
| Net income | -$86.5M | -$131.8M | -$134.5M | -$166.0M | -$246.0M | -$378.0M |
| Diluted EPS | -$2.81 | -$3.59 | -$2.26 | -$1.99 | -$2.47 | -$3.29 |
| Operating cash flow | -$60.3M | -$126.8M | -$132.7M | -$145.2M | -$200.9M | -$300.0M |
| Free cash flow | -$64.4M | -$132.0M | -$133.8M | -$145.3M | -$201.0M | -$300.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -564.0% | -690.5% | -404.8% | — | — | — |
| Net margin | -561.5% | -700.5% | -405.2% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 | — | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$59.5M | -$64.8M | -$69.4M | -$77.1M | -$112.1M | -$103.5M | -$91.9M | -$102.0M |
| Net income | -$58.5M | -$64.5M | -$66.2M | -$74.7M | -$110.0M | -$102.2M | -$91.0M | -$105.5M |
| Diluted EPS | -$0.60 | -$0.66 | -$0.62 | -$0.67 | -$0.98 | -$0.90 | -$0.74 | -$0.83 |
| Operating cash flow | -$49.2M | -$52.5M | -$49.5M | -$78.7M | -$76.9M | -$68.9M | -$75.5M | -$82.1M |
| Free cash flow | -$49.2M | -$52.5M | -$49.5M | -$78.9M | -$77.2M | -$69.0M | -$75.5M | -$82.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 20, 2026
- 9h agoScholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)finance.yahoo.com
- 12h agoBristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide makerbiopharmadive.com
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Peng Katie | Sale | 2,988 | $53.56 | $160,036.68 | filing |
| 2026-07-01 | Peng Katie | Sale | 2,437 | $54.25 | $132,213.59 | filing |
| 2026-07-01 | Reed Joshua | Sale | 2,105 | $53.50 | $112,608.66 | filing |
| 2026-07-01 | Burow Kristina | Sale | 2,105 | $53.49 | $112,604.87 | filing |
| 2026-07-01 | FLIER JEFFREY S. | Sale | 1,568 | $53.53 | $83,939.43 | filing |
| 2026-07-01 | FLIER JEFFREY S. | Sale | 1,470 | $54.24 | $79,727.66 | filing |
| 2026-07-01 | Gilman Michael | Sale | 1,346 | $53.54 | $72,070.22 | filing |
| 2026-07-01 | Gilman Michael | Sale | 1,155 | $54.23 | $62,630.68 | filing |
| 2026-07-01 | Burow Kristina | Sale | 948 | $54.28 | $51,458.96 | filing |
| 2026-07-01 | Reed Joshua | Sale | 948 | $54.28 | $51,458.77 | filing |
| 2026-07-01 | Gilman Michael | Sale | 43 | $54.81 | $2,357.02 | filing |
| 2026-07-01 | Peng Katie | Sale | 21 | $54.96 | $1,154.25 | filing |
| 2026-07-01 | FLIER JEFFREY S. | Sale | 15 | $54.88 | $823.14 | filing |
| 2026-06-04 | Reed Joshua | Award | 6,839 | $0.00 | $0.00 | filing |
| 2026-06-04 | FLIER JEFFREY S. | Award | 6,839 | $0.00 | $0.00 | filing |
| 2026-06-04 | Brudnick Richard | Award | 6,839 | $0.00 | $0.00 | filing |
| 2026-06-04 | Burow Kristina | Award | 6,839 | $0.00 | $0.00 | filing |
| 2026-06-04 | Gilman Michael | Award | 6,839 | $0.00 | $0.00 | filing |
| 2026-06-04 | Peng Katie | Award | 6,839 | $0.00 | $0.00 | filing |
| 2026-06-04 | AKKARAJU SRINIVAS | Award | 6,839 | $0.00 | $0.00 | filing |
| 2026-04-23 | Burow Kristina | Option exercise | 36,000 | $9.11 | $327,960.00 | filing |
| 2026-04-23 | Burow Kristina | Option exercise | 7,800 | $26.78 | $208,884.00 | filing |
| 2026-04-23 | Burow Kristina | Option exercise | 18,000 | $8.36 | $150,480.00 | filing |
| 2026-04-23 | Burow Kristina | Option exercise | 28,000 | $4.75 | $133,000.00 | filing |
| 2026-04-16 | Hallal David· Chief Executive Officer | Sale | 30,615 | $49.57 | $1.5M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.